Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Down 11.1% in March

Eterna Therapeutics Inc. (NASDAQ:ERNAGet Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 33,600 shares, a decline of 11.1% from the February 29th total of 37,800 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is currently 2.7 days. Currently, 1.1% of the shares of the stock are short sold.

Eterna Therapeutics Price Performance

Shares of ERNA stock traded up $0.05 during trading on Tuesday, hitting $2.35. The company had a trading volume of 7,895 shares, compared to its average volume of 10,071. The firm has a market capitalization of $12.71 million, a P/E ratio of -0.58 and a beta of 4.16. Eterna Therapeutics has a one year low of $0.84 and a one year high of $3.75. The company has a debt-to-equity ratio of 3.03, a quick ratio of 1.46 and a current ratio of 1.46. The stock’s 50-day moving average price is $1.91 and its 200 day moving average price is $1.72.

Eterna Therapeutics (NASDAQ:ERNAGet Free Report) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($1.14) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ERNA. Goldman Sachs Group Inc. acquired a new position in Eterna Therapeutics in the 2nd quarter worth about $26,000. Geode Capital Management LLC acquired a new position in shares of Eterna Therapeutics in the fourth quarter valued at approximately $45,000. Sippican Capital Advisors raised its holdings in Eterna Therapeutics by 60.0% in the 2nd quarter. Sippican Capital Advisors now owns 21,601 shares of the company’s stock valued at $49,000 after buying an additional 8,101 shares during the last quarter. Vanguard Group Inc. boosted its position in Eterna Therapeutics by 30.6% during the 3rd quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock worth $54,000 after buying an additional 5,830 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Eterna Therapeutics during the 4th quarter worth approximately $56,000. 70.55% of the stock is currently owned by institutional investors.

About Eterna Therapeutics

(Get Free Report)

Eterna Therapeutics Inc operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.

Read More

Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with's FREE daily email newsletter.